Podcasts

Articles

Webinars

Peer-Reviewed

Videos

ASH: American Society of Hematology

There are 2 such vaccines now in use in the United States; the Pfizer-BioNTech vaccine is fully approved for the first 2 doses for those 16 and older, and the Moderna vaccine has an emergency use authorization for those 18 and older.

Third mRNA COVID-19 Vaccine Helps Some Patients With Blood Cancer Produce Antibodies for First Time

John Burke, MD, hematologist, Rocky Mountain Cancer Centers, discussed findings of the late-breaking abstract session POLARIX presented at ASH 2021, which compared pola-R-CHP with standard-of-care R-CHOP in patients with previously untreated DLBCL.

Dr John Burke: POLARIX Shows Marked Improvement in Patient Outcomes With Pola-R-CHP as First-line Treatment for DLBCL

Results presented at the 63rd Annual American Society of Hematology Meeting showed that using polatuzumab vedotin instead of vincristine in R-CHOP improved progression-free survival in patients with newly diagnosed diffuse large B-cell lymphoma.

POLARIX: Upgrading R-CHOP With Polatuzumab Vedotin for Vincristine Improves Progression-Free Survival 

Frederick Locke, MD, vice chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy Program, co-leader, Immuno-Oncology, Moffitt Cancer Center, discusses findings of the phase 3 ZUMA-7 trial presented at ASH 2021 and how use of axicabtagene ciloleucel can be optimally applied in a real-world setting.

Dr Frederick Locke on Real-World Implications of ZUMA-7 Findings in Relapsed/Refractory LBCL

Sattva S. Neelapu, MD, professor and deputy department chair in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, discusses findings of the ZUMA-12 study examining axicabtagene ciloleucel (axi-cel) as a first-line treatment option for high-risk patients with large B-cell lymphoma.

Dr Sattva Neelapu: Axi-Cel Highly Effective as First-line Option in High-Risk Large B-Cell Lymphoma

Two-third of those who receive a chronic lymphocytic leukemia (CLL) diagnosis are age 65 or older, so the ease with which drugs are covered in Medicare has an outsized role in patient access to care. 

Most Medicare Beneficiaries With CLL Diagnosis Don’t Get Therapy, Claims Analysis Finds

Mark Wildgust, PhD, vice president, Global Medical Affairs, Oncology, Janssen, speaks on progression-free survival, complete response, and overall survival benefits observed with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 and other studies presented at the 63rd Annual American Society of Hematology Meeting and Exposition.

Dr Mark Wildgust Reviews Key Cilta-Cel Research Presented at ASH 2021

Frederick L. Locke, MD, of Moffitt Cancer Center in Tampa, Florida, is the lead study author of the phase 3 ZUMA-7 trial, which examined the use of axi-cel in second-line treatment of patients with relapsed or refractory large B-cell lymphoma (R/R LBCL).

ZUMA-7: Axi-Cel in Second Line Is the “New Standard” in R/R LBCL, Locke Says

Lori Muffly, MD, associate professor of medicine, Blood & Marrow Transplantation, Stanford University, discusses findings of her study showing disparities in clinical trial enrollment and patient outcomes for at-risk pediatric minority populations with acute lymphoblastic leukemia (ALL).

Dr Lori Muffly Spotlights Disparities in Clinical Trial Enrollment, Patient Outcomes in Pediatric ALL

Zanubrutinib produced prolonged progression-free survival (PFS) compared with a combination of bendamustine and rituximab among treatment-naïve patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL).